The VITARNA Story
VitaDAO’s initial support for Artan Bio, via a Sponsored Research Agreement (SRA), has been to fund the design and validation of their engineered suppressor system (VDP-103) in cells with targetable mutations to confirm validity of the approach.
Artan Bio seeks to continue development of the engineered suppressor system beyond the initial project with VitaDAO to further the IP development, and further validate the system in animal models to support preclinical translation and establish a development candidate for use in clinical trials.
The Artan Bio funding application is submitted
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.
Funding for Artan Bio via IP-NFT successfully approved by $VITA token holders
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.
VitaDAO token holders vote to Tokenize the Artan Bio IP-NFT
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.
The VITARNA IPT is developed, public sale is announced
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.
Funding Secured!
VitaDAO has successfully tokenized the IP-NFT, Artan Bio, and raised $300K
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.
VitaRNA by ArtanBIO - Data Drop
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.